

Quarterly Results announcement form

Name of listed company :Essex Bio-Technology Limited

Stock code :8151

Year end date :31/12/2002

Important Note :

This result announcement form only contains extracted information from and should be read in conjunction with the detailed results announcement of the issuer, which can be viewed on the GEM website at <http://www.hkgem.com>

Currency: HK\$'000

Quarterly Results Announcement	(Unaudited) Current Period from 01/01/2002 to 31/03/2002 HK\$'000	(Unaudited) Last Corresponding Period from 01/01/2001 to 31/03/2001 HK\$'000
Turnover	5,428	4,101
Profit/(Loss) from Operations :	(453)	(294)
Finance cost :	(6)	(17)
Share of Profit/(Loss) of Associates :	0	0
Share of Profit/(Loss) of Jointly Controlled Entities :	0	0
Profit/(Loss) after Taxation & MI :	(459)	(311)
% Change Over the Last Period :	N/A %	
EPS / (LPS) - Basic :	(0.06 cent)	(0.09 cent)
- Diluted :	N/A	N/A
Extraordinary (ETD) Gain/(Loss) :	0	0
Profit (Loss) after ETD Items :	(459)	(311)
1st Q Dividend per Share :	NIL	NIL
(specify if with other options) :	N/A	N/A
B/C Dates for 1st Q Dividend :	N/A to	N/A bdi.
Payable Date :	N/A	
B/C Dates for AGM/SGM :	N/A to	N/A bdi.
Other Distribution for Current Period :	NIL	
B/C Dates for Other Distribution :	N/A to	N/A bdi.

(bdi: both days inclusive)

For and on behalf of
Essex Bio-Technology Limited

Signature :
Name : Fang Hai Zhou
Title : Managing Director

Responsibility statement

The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this results announcement form (the "Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information are accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make the Information herein inaccurate or misleading. The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

Remarks:

1. Basis of presentation

The principal accounting policies adopted in preparing the unaudited consolidated results conform to the Statements of Standard Accounting Practice issued by the Hong Kong Society of Accountants.

2. Tax

No provision for Hong Kong profits tax has been made as the Group had no assessable profit in Hong Kong for the three months ended 31 March 2002 and the corresponding period in 2001.

The Group's operating subsidiaries in the PRC are all established and carrying on business in the Special Economic Zones of the PRC as foreign investment enterprises. They are subject to the enterprise income tax at a concessionary rate of 15%. One of the Group's subsidiaries, which is engaged in production, is entitled to seek exemption from the enterprise income tax for two years starting from the first year of profitable operations after offsetting accumulated losses brought forward, followed by a 50% reduction in enterprise income tax for the next three years. No provision for the PRC enterprise income tax has been made as there was no net assessable income for the three months ended 31 March 2002 and the corresponding period in 2001 after off-setting accumulated losses brought forward.

No recognition of the potential deferred taxation asset relating to tax losses has been made as the recoverability of this potential deferred taxation asset is uncertain.

3. Loss per share

The calculation of the basic loss per share for the three months ended 31 March 2002 is based on

the unaudited loss attributable to shareholders of HK\$323,000 and the weighted average number of 512,820,000 ordinary shares outstanding.

The 384,610,666 ordinary shares outstanding as a result of the Group's Reorganization prior to the Placing of its shares in June 2001, are included in the calculation of the weighted average number of shares as if those shares had been in issue since 1 January 2001.

The exercise of the pre-IPO share options granted by the Company would have an anti-dilutive effect on the loss per share for the three months ended 31 March 2002 and 2001.

4. Dividends

The directors do not recommend the payment of an interim dividend for the three months ended 31 March 2002 (2001: Nil).

5. Turnover

Turnover comprises total invoiced value of biopharmaceutical products, skincare products and pharmaceutical research and development projects sold after allowances for returns and discounts.